Biohaven Ltd. (BHVN) is a publicly traded Healthcare sector company. As of May 21, 2026, BHVN trades at $8.94 with a market cap of $1.28B and a P/E ratio of -0.60. BHVN moved +5.66% today. Year to date, BHVN is -10.88%; over the trailing twelve months it is -45.54%. Its 52-week range spans $7.48 to $55.70. Analyst consensus is buy with an average price target of $19.60. Rallies surfaces BHVN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Biohaven Prepares Mid-2026 Pivotal IgAN, Graves' Trials with $351.8M Cash: Biohaven ended Q1 2026 with $351.8 million in cash and equivalents and cut R&D spend by $83.8 million year-over-year to $103.8 million. The company plans mid-2026 starts for pivotal IgAN and Graves' disease trials, with epilepsy topline data and obesity study results expected in the second half of the year.
| Metric | Value |
|---|---|
| Price | $8.94 |
| Market Cap | $1.28B |
| P/E Ratio | -0.60 |
| EPS | $-14.83 |
| Dividend Yield | 0.00% |
| 52-Week High | $55.70 |
| 52-Week Low | $7.48 |
| Volume | 52 |
| Avg Volume | 0 |
| Revenue (TTM) | $859.68M |
| Net Income | $-930.69M |
| Gross Margin | 85.63% |
12 analysts cover BHVN: 0 strong buy, 8 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $19.60.